OSI-7904
OSI-7904 is a liposomal tetrahydrouridine (THU) prodrug of the antineoplastic fluoropyrimidine 5-fluorouracil (5-FU). It is developed by OSI Pharmaceuticals and is currently in clinical trials for the treatment of various types of cancer.
Mechanism of Action[edit]
OSI-7904 is a prodrug that is converted into 5-FU in the body. 5-FU is a fluoropyrimidine drug that inhibits thymidylate synthase, an enzyme necessary for DNA synthesis. By inhibiting this enzyme, 5-FU disrupts DNA synthesis and prevents the growth and proliferation of cancer cells.
The liposomal formulation of OSI-7904 allows for targeted delivery of the drug to cancer cells, reducing the systemic toxicity associated with 5-FU. The liposomes are designed to accumulate in the tumor tissue, where they release the drug directly into the cancer cells.
Clinical Trials[edit]
OSI-7904 has been tested in several clinical trials for the treatment of various types of cancer, including colorectal cancer, pancreatic cancer, and non-small cell lung cancer. The results of these trials have shown that OSI-7904 has a favorable safety profile and shows promise as a potential treatment for these types of cancer.
Future Directions[edit]
Further clinical trials are needed to determine the optimal dosing and administration schedule for OSI-7904, as well as to evaluate its efficacy in combination with other anticancer drugs. OSI Pharmaceuticals is currently conducting these trials.
See Also[edit]
